Biotech Valuation – A playbook for deal makers

1,000 SEK + VAT

What is your valuation based on? The dreaded question most CEOs, with pre-commercial drugs in their pipelines, hate to answer. Investors and Big Pharma executives of course know that any financial model will be inherently imprecise – yet they want you to present a valuation based on logical and data-driven assumptions.

This book aims to guide you through the basic mechanics of biotech valuation and provide benchmark data and references that may serve as assumptions about key factors. Our goal has been to create something actionable for CEOs, business developers, board members and investors in small biotech companies to use when preparing negotiations for financing rounds or business deals. Our presented cases, benchmarks and examples are based on the aggregated experience from 500+ strategy projects for clients in the Life Science industry.

Now more than ever, it is important for biotech executives to be able to clearly communicate value drivers and manage key uncertainties of their pre-commercial assets. In a world where short-term share performance is on a collision course with reality, we provide you with the tools to systematically identify and articulate the value of your development programs when negotiating your next deal.

The book Biotech Valuation – A playbook for deal makers is complimentary if you sign up for one of our courses.

Shipping is only available within the European Union. If you’re in an area outside of the European Union, please email us at msc@mscnordics.com for more information.

SKU: 1 Category:

What is your valuation based on? The dreaded question most CEOs, with pre-commercial drugs in their pipelines, hate to answer. Investors and Big Pharma executives of course know that any financial model will be inherently imprecise – yet they want you to present a valuation based on logical and data-driven assumptions.

This book aims to guide you through the basic mechanics of biotech valuation and provide benchmark data and references that may serve as assumptions about key factors. Our goal has been to create something actionable for CEOs, business developers, board members and investors in small biotech companies to use when preparing negotiations for financing rounds or business deals. Our presented cases, benchmarks and examples are based on the aggregated experience from 500+ strategy projects for clients in the Life Science industry.

Now more than ever, it is important for biotech executives to be able to clearly communicate value drivers and manage key uncertainties of their pre-commercial assets. In a world where short-term share performance is on a collision course with reality, we provide you with the tools to systematically identify and articulate the value of your development programs when negotiating your next deal.

The book Biotech Valuation – A playbook for deal makers is complimentary if you sign up for one of our courses.

Shipping is only available within the European Union. If you’re in an area outside of the European Union, please email us at msc@mscnordics.com for more information.